364 related articles for article (PubMed ID: 25082530)
1. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
[TBL] [Abstract][Full Text] [Related]
2. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
[TBL] [Abstract][Full Text] [Related]
3. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
[TBL] [Abstract][Full Text] [Related]
4. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.
Stein BL; Williams DM; Rogers O; Isaacs MA; Spivak JL; Moliterno AR
Exp Hematol; 2011 Jan; 39(1):95-101. PubMed ID: 20888389
[TBL] [Abstract][Full Text] [Related]
5. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
Tefferi A; Pardanani A; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Gangat N; Finke CM; Schwager S; Mullally A; Li CY; Hanson CA; Mesa R; Bernard O; Delhommeau F; Vainchenker W; Gilliland DG; Levine RL
Leukemia; 2009 May; 23(5):905-11. PubMed ID: 19262601
[TBL] [Abstract][Full Text] [Related]
6. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
[TBL] [Abstract][Full Text] [Related]
7. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice.
Ishii T; Zhao Y; Sozer S; Shi J; Zhang W; Hoffman R; Xu M
Exp Hematol; 2007 Nov; 35(11):1633-40. PubMed ID: 17764815
[TBL] [Abstract][Full Text] [Related]
8. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
[TBL] [Abstract][Full Text] [Related]
9. Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.
Swierczek SI; Yoon D; Bellanné-Chantelot C; Kim SJ; Saint-Martin C; Delhommeau F; Najman A; Prchal JT
Haematologica; 2011 May; 96(5):775-8. PubMed ID: 21273266
[TBL] [Abstract][Full Text] [Related]
10. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.
Wang X; LeBlanc A; Gruenstein S; Xu M; Mascarenhas J; Panzera B; Wisch N; Parker C; Goldberg JD; Prchal J; Hoffman R; Najfeld V
Exp Hematol; 2009 Oct; 37(10):1194-200. PubMed ID: 19615425
[TBL] [Abstract][Full Text] [Related]
11. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
Vainchenker W; Kralovics R
Blood; 2017 Feb; 129(6):667-679. PubMed ID: 28028029
[TBL] [Abstract][Full Text] [Related]
12. Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720-2A>G variant.
Kanduła Z; Kroll-Balcerzak R; Lewandowski K
J Clin Lab Anal; 2022 May; 36(5):e24388. PubMed ID: 35435261
[TBL] [Abstract][Full Text] [Related]
13. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.
Mullally A; Poveromo L; Schneider RK; Al-Shahrour F; Lane SW; Ebert BL
Blood; 2012 Jul; 120(1):166-72. PubMed ID: 22627765
[TBL] [Abstract][Full Text] [Related]
14. JAK2 V617F allele burden in polycythemia vera: burden of proof.
Moliterno AR; Kaizer H; Reeves BN
Blood; 2023 Apr; 141(16):1934-1942. PubMed ID: 36745865
[TBL] [Abstract][Full Text] [Related]
15. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.
Levine RL; Belisle C; Wadleigh M; Zahrieh D; Lee S; Chagnon P; Gilliland DG; Busque L
Blood; 2006 May; 107(10):4139-41. PubMed ID: 16434490
[TBL] [Abstract][Full Text] [Related]
16. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.
Helbig G; Wieczorkiewicz A; Woźniczka K; Wiśniewska-Piąty K; Rusek A; Kyrcz-Krzemień S
Med Oncol; 2012 Dec; 29(4):2379-84. PubMed ID: 22383244
[TBL] [Abstract][Full Text] [Related]
17. ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients.
Andréasson B; Pettersson H; Wasslavik C; Johansson P; Palmqvist L; Asp J
Br J Haematol; 2020 Jun; 189(5):913-919. PubMed ID: 32066200
[TBL] [Abstract][Full Text] [Related]
18. [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].
Bai J; Xue YP; Zhang L; Li CH; Fan DM; Li B; Xu SC; Li DP; Sun XJ; Jiang B; Yang RC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):444-9. PubMed ID: 21518505
[TBL] [Abstract][Full Text] [Related]
19. Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.
Stetka J; Vyhlidalova P; Lanikova L; Koralkova P; Gursky J; Hlusi A; Flodr P; Hubackova S; Bartek J; Hodny Z; Divoky V
Oncogene; 2019 Jul; 38(28):5627-5642. PubMed ID: 30967632
[TBL] [Abstract][Full Text] [Related]
20. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
